Effects of Xuezhikang on Hyperlipidemia, Abnormal Hemorrheology and Microcirculation Disorders
Zhang Ningxin, LuMeixia, Wang Limin
(Shekou People's Hospital of Shenzhen, China 518067)
Journal of Chinese Microcirculation,
March 1999, 3(1):51-52


Lipid metabolic disorders, hemorrheological abnormality and microcirculation disturbance have become one of the major reasons for the development of cardio-cerebrovascular diseases such as atherosclerosis, myocardial infarction and cerebrovascular accidents. In this study, we used Xuezhikang to treat 70 hyperlipoidemia patients to investigate its curative effects on lipid level, hemorrheology and nailbed microcirculation. Here is the detail.


42 men, 28 women were chosen aging from 36 ~ 68 years old averaging 56.8. The 70 patients had high serum lipid levels with 35 cases TC increase, 40 cases of TG increase and 20 cases of HDL-C decrease. They all presented hemorrheological abnormalities and nailbed microcirculation disturbance. In addition, 32 target patients complicated with coronary heart disease, 23 patients with hypertension, 9 with cerebrovascular disorders and 6 with diabetes.

Administration Method
Xuezhikang capsule, [(1995) approval code Z-94 by the Ministry of Public Health], developed by Beijing WBL Peking University Biotech Co., Ltd., was administrated by target patients with 0.6 g each time, twice a day. Each capsule contains 0.3 g Xuezhikang. The treatment lasted for 2 months.

Observation Methods
Self-comparison approach was adopted in the study. During the administration of Xuezhikang, other lipid-regulating agents or blood viscosity improving medicine were prohibited. Conventional blood and urine test, electrocardiogram, blood sugar, hepatic and renal functions, serum lipid level, hemorrheology and nailbed microcirculation were examined before the treatment. The above examinations were repeated 2-month after the administration. Pre- and post-treatment data matching t-test was utilized for statistic process.


Effects on Serum Lipid
Efficacy of Xuezhikang on TC, TG and HDL-C abnormalities was 79.7%, 72.5% and 75% respectively. (See Table I)

Table I. Efficacy of Xuezhikang on Abnormal Serum Lipid Concentrations (case,%)
Highly Effective
Efficacy (%)
12 (34.2)
16 (45.7)
5 (14.3)
2 (5.8)
14 (35.0)
15 (37.5)
8 (20.0)
3 (7.5)
6 (30.0)
9 (45.0)
4 (20.0)
1 (5.0)

Reduction Degree on Serum Lipid
TC decreased by 24.9%, TG reduced by 30.2% and HDL-C went up by 28.5%.
(See Table II) It demonstrated that Xuezhikang has dramatic performance in reducing the concentrations of TC and TG while improving HDL-C level.

Table II. Serum Lipid Concentration Changes before and after Xuezhikang Treatment (mmol/L, X s)
Before Treatment
After Treatment
Change (%)
P Value
7.32 1.20
5.49 2.60
< 0.05
1.66 0.24
1.16 0.61
< 0.05
0.86 0.20
1.21 0.43
< 0.05

Effects on Hemorrheology and Nailbed Microcirculation
Observation found that Xuezhikang significantly suppressed platelet aggregation, improved blood viscosity and plasma viscosity, and reduced the level of fibrinogen. It possessed obvious performance in improving microcirculation. Moreover, both loop form, blood flow and weighted peripheral integration value of loop reduced under its influence. (See Table III and Table IV)

Table III. Effects of Xuezhikang on Abnormal Hemorrheology (X s)
Before Treatment
After Treatment
P Value
Platelet Viscosity
52.6 0.52
41.37 7.31
< 0.05
Blood Specific Viscosity (mpa.s)
4.26 0.50
3.81 0.65
< 0.05
Plasma Specific Viscosity (mpa.s)
1.72 0.37
1.51 0.25
< 0.05
Fibrinogen (g/L)
4.58 0.95
3.68 0.39
< 0.05

Table IV. Effects of Xuezhikang on Weighted Integral of Nailbed Microcirculation (X s)
Before Treatment
After Treatment
P Value
1.45 0.92
1.38 0.81
Blood Flow
2.15 0.75
1.21 0.85
< 0.01
Peripheral Loop
1.24 0.83
1.06 0.66
< 0.05
Overall Integral
4.84 1.56
3.65 1.42
< 0.01

No side-effects appeared in the course of the administration or in post-treatment examinations. And there were no obvious changes in the levels of erythrocyte, leukocyte and platelet. Nor did any significant changes occur in hepatic and renal functions.


The main ingredients of Xuezhikang come from refined extract of Monascus purpureus (red yeast) rice. Currently, it is thought that its lipid regulating mechanism lies in the existence of rich HMG-CoA reductase inhibitor, unsaturated fatty acid and various kinds of necessary amino acids. They possess specific competitive inhibition against HMG-CoA reductase, reduce the formation of TC and lower serum TC level. Meanwhile, they can remarkably decrease serum TG and increase HDL-C level. Pharmacological experiment has demonstrated that Xuezhikang could not only reduce serum TC and TG (of rabbit or quail models) significantly, but also inhibit the development of atherosclerosis and lipid deposition in the liver of hyperlipoidemia rabbits.

  • Recent reports on clinical effects of Xuezhikang on primary hyperlipoidemia also demonstrate lipid regulation strength of 1.2 g/d Xuezhikang being similar to that of 10 mg/d Mavastatin but with less side-reactions.
  • Lipid metabolic disorder is the key factor leading to the increase of plasma viscosity. However, Xuezhikang may reduce blood viscosity and platelet aggregation by improving serum lipid metabolism, and subsequently improve hemorrheology and microcirculation. This study demonstrated that Xuezhikang possesses the above functions without any side-effects. Therefore, it can be utilized as an effective clinical medicine to treat hyperlipoidemia and prevent and cure cardio-cerebrovascular diseases.


Zhu Yan, Li Changling, Wang Yinye, Lipid Regulation Effects of Xuezhikang on Hyperlipoidemia Rabbit and Quail Models, Journal of Chinese Medicine, 1995, 30:656.
Kou Zhirong, Lu Zongliang, et al, Clinical Effects of Xuezhikang on Primary Hyperlipoidemia, Chinese Journal of Internal Medicine, 1997, 36:529.
2013 Asiapharm Biotech Pte Ltd. All rights reserved.

Notices and Legal Disclaimer

Information on this web site is provided for informational purposes only and is not a substitute for professional medical advice. You should not use the information on this web site for diagnosing or treating a medical or health condition. You should carefully read all product packaging. If you have or suspect you have a medical problem, promptly contact your professional healthcare provider.

Statements and information regarding dietary supplements have not been evaluated or approved by the U.S. Food and Drug Administration. Please consult your healthcare provider before beginning any course of supplementation or treatment.